Navigation Links
Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells
Date:1/20/2011

GAITHERSBURG, Md., Jan. 20, 2011 /PRNewswire/ -- MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors. The study, published in the February 1 issue of Cancer Research (a journal of the American Association for Cancer Research), suggests that MEDI-573 inhibits multiple biological pathways related to cancer.  

MEDI-573 is the only human monoclonal antibody (MAb) currently under clinical development that neutralizes both insulin-like growth factor (IGF)-I and IGF-II, growth hormones that regulate cell growth, survival, differentiation, and transformation (i.e., the process of acquiring cancerous characteristics). This MedImmune compound specifically inhibits IGF signaling through two important pathways: IGF-1R and IR-A (insulin receptor isoform A). Unlike the other IGF-1R-targeting MAbs in development that target only IGF-1R, MEDI-573 neutralizes both the receptors IGF-1R and IR-A as well as their hybrid receptors.  In addition, MEDI-573 spares the insulin receptor isoform B (IR-B), which interacts with insulin and is crucial for the metabolism of glucose – the body's main source of energy. Therapies that affect IR-B have been shown to raise or drop blood sugar levels, both of which can cause serious health problems. Preliminary data from MedImmune's first-time-in-human study suggest that MEDI-573 does not alter glucose homeostasis.

"MEDI-573 represents an innovative approach for the treatment of solid tumors with the potential for greater and more consistent inhibition of cancer cell growth than treatments that only target one pathway," said Jin Gao, Ph.D., Scientist II in Oncology Research at MedImmune and lead author of the study.  "The data from our pre-clinical studies are highly promising.  Ongoing studies in humans will pr
'/>"/>

SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
3. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
4. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
5. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
6. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
7. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
8. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
9. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
10. Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps
11. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, ... unmet medical needs using RNA-targeted technologies, today ... (RXI-109-1402) with RXI-109, for the reduction of ... revision surgery, has been initiated. ...
(Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... contract from the U.S. Environmental Protection Agency (EPA). ... expertise in developmental toxicity models, including tests designed ... neuron formation and the formation of connections between ... Inhibition of neurodifferentiation and synapse formation by environmental ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
(Date:7/29/2014)... hurdled a number of significant technological challenges in ... technology originally created for the James Webb Space ... Harvey Moseley, a scientist at NASA,s Goddard Space ... electrostatically actuated microshutter arrays that is, those ... as functional as the current technology,s magnetically activated ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... 30 Rib-X Pharmaceuticals, Inc., a development stage company focused ... treatment of antibiotic resistant infections, announced today that Russell Greig, ... the Company,s Board of Directors. Rib-X,s board now consists ... pleased that Russell Greig has joined the Rib-X Board of ...
... ... Northern Irish packaging machinery manufacturer, Sepha Ltd. is breaking into one of ... testing and de-blistering machines for the first time there ... Ahead of its presence at Interphex, Sepha has already received ...
... /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL ),today ... Plan which,closed on 24 June 2009. Shareholders of the ... of shares each at the $2.35 price,paid by institutional investors ... total of 1,584 shareholders participated in the plan under which ...
Cached Biology Technology:Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors 2Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors 3Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland 2Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland 3Pharmaxis Closes Share Purchase Plan 2
(Date:7/30/2014)... could be as simple as inserting a medicated, disappearing ... Washington bioengineers have discovered a potentially faster way to ... HIV. Their method spins the drug into silk-like fibers ... higher doses of the drug than possible with other ... could offer women a potentially more effective, discreet way ...
(Date:7/30/2014)... figured out how to create colors, nature had already ... of many different hues, for example. Now scientists are ... friendly way to make colored plastics. Their paper on ... materials rather than dyes, to produce color appears ... N. Asger Mortensen, Anders Kristensen and colleagues point out ...
(Date:7/30/2014)... awarded the Scientific Committee on Antarctic Research,s (SCAR) ... SCAR, an inter-disciplinary international science body, initiates, develops ... the Antarctic region, and on the role of ... organisation also provides scientific advice about Antarctica to ... region. , The medal is open internationally to ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... CORVALLIS, Ore. An international group of more than 30 ... their contribution to the health of the world,s oceans, which ... identified food provision, tourism and recreation as leading concerns. ... each nation on a 0-100 scale in 10 separate categories ...
... on fetal growth have consistently demonstrated deficits that persist ... human studies have been inconsistent. A new study ... on growth and body composition throughout childhood has found ... age, as well as a delay in weight gain ...
... cells has provided scientists at Dana-Farber Cancer Institute and the ... entirely new class of genes that may serve as an ... in the Aug. 17 issue of the journal Cell ... of which had previously been identified as potential targets for ...
Cached Biology News:Rating of ocean health shows 'room for improvement' 2Tracking the effects of prenatal alcohol exposure through to 9 years of age 2Tracking the effects of prenatal alcohol exposure through to 9 years of age 3'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 2'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 3
... is most widely used in combination ... differentially stain nucleic acids following polyacrylamide ... solution, Pyronin Y stains RNA red, ... Chem comp: Dye content ...
... The loxP-cm-loxP cassette is ... prokaryotic cells. The prokaryotic promoter ... resistance is a slightly modified version ... higher transcription efficiency than the generally ...
... Agencourt AMPure is a ... that requires no sample transfer, ... efficiently purifies small and large ... or 384-well microplates. Agencourt AMPure ...
... is a magnetic bead-based PCR ... sample transfer, centrifugation or filtration ... and large PCR extension products ... Agencourt AMPure can easily be ...
Biology Products: